Form 4: IGM Biosciences Chief Scientific Officer Bruce Keyt Reports Stock Transactions

Bruce Keyt, Chief Scientific Officer of IGM Biosciences, reports the acquisition and disposition of company stock, including purchases under the employee stock purchase plan and sales to cover tax obligations.

Summary

• On May 15, 2024, Bruce Keyt, the Chief Scientific Officer of IGM Biosciences, acquired 3,000 shares of common stock at a price of $5.02 per share through the company's Employee Stock Purchase Plan.
• On June 14, 2024, Keyt sold 1,106 shares of common stock at a weighted average price of $7.5753 per share to cover tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Keyt directly owns 197,769 shares of IGM Biosciences common stock and indirectly owns 4,039 shares held by his spouse.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions are routine and do not indicate a significant shift in the executive's holdings or confidence.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan indicates Keyt's continued investment in the company.

Negatives

• The sale of shares to cover tax obligations, while common, could be perceived negatively by some investors.

Industry Context

Form 4 filings are a routine part of insider trading activity and are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders' perception of management's confidence in the company.

Key Dates